At Achiko, we have created a multi-faceted, multi-layered approach to managing the current Covid-19 pandemic, where the goal is to achieve virus control. Together with social distancing, mask wearing, hand hygiene and of course the unprecedented innovation in vaccine technology, testing will continue to play an important role. Achiko contributes a user-friendly technological solution that harnesses the power of track and trace, and cohesively aligns that to cutting edge biotechnology innovation.
In unlocking DNA aptamer technology, our diagnostic protocols have developed a saliva-based testing kit with Project Gumnuts, which harnessed to our Teman Sehat (Health Buddy) mobile apps, delivers rapid quantitative and qualitative testing, and healthcare expertise for the detection of Covid-19 and other pathogens.
Initial trials have been completed in Spain and Indonesia, and we have partnered with research institutes to better understand the acceptance and practicality of undertaking mass testing within a segment of those populations.
Headquartered in Zurich, our entrepreneurial and multidisciplinary team have developed and are commercialising a leading diagnostic platform for the detection of Covid-19, and other human pathogens. Achiko has an international footprint, specialising in research innovation, biotechnology, healthcare and mobile application development, stemming from Switzerland, Spain, Singapore, Southeast Asia and Australia.
Achiko AG is listed on the SIX Swiss Exchange
SWX: ACHI, ISIN CH0522213468